Hasil Pencarian - David Venet

  • Menampilkan 1 - 13 hasil dari 13
Perbaiki Hasil
  1. 1
    A measure of the signal-to-noise ratio of microarray samples and studies using gene correlations.

    A measure of the signal-to-noise ratio of microarray samples and studies using gene correlations. oleh David Venet, Vincent Detours, Hugues Bersini

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Most random gene expression signatures are significantly associated with breast cancer outcome.

    Most random gene expression signatures are significantly associated with breast cancer outcome. oleh David Venet, Jacques E Dumont, Vincent Detours

    Diterbitkan 2011-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer

    Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer oleh Bastien Nguyen, David Venet, Matteo Lambertini, Christine Desmedt, Roberto Salgado, Hugo Mark Horlings, Françoise Rothé, Christos Sotiriou

    Diterbitkan 2019-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis

    Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis oleh Françoise Rothé, David Venet, Dieter Peeters, Ghizlane Rouas, Mattia Rediti, Dominiek Smeets, Floriane Dupont, Peter Campbell, Diether Lambrechts, Luc Dirix, Christos Sotiriou, Michail Ignatiadis

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome

    Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome oleh David Venet, Danai Fimereli, Françoise Rothé, Bram Boeckx, Marion Maetens, Samira Majjaj, Ghizlane Rouas, Maria Capra, Giuseppina Bonizzi, Federica Contaldo, Christine Galant, Martine Piccart, Giancarlo Pruneri, Denis Larsimont, Diether Lambrechts, Christine Desmedt, Christos Sotiriou

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

    FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer oleh Andrea Gombos, David Venet, Lieveke Ameye, Peter Vuylsteke, Patrick Neven, Vincent Richard, Francois P. Duhoux, Jean-Francois Laes, Françoise Rothe, Christos Sotiriou, Marianne Paesmans, Ahmad Awada, Thomas Guiot, Patrick Flamen, Martine Piccart-Gebhart, Michail Ignatiadis, Géraldine Gebhart

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

    Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer oleh Andrea Gombos, David Venet, Lieveke Ameye, Peter Vuylsteke, Patrick Neven, Vincent Richard, Francois P. Duhoux, Jean-Francois Laes, Françoise Rothe, Christos Sotiriou, Marianne Paesmans, Ahmad Awada, Thomas Guiot, Patrick Flamen, Martine Piccart-Gebhart, Michail Ignatiadis, Géraldine Gebhart

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Timing evolution of lobular breast cancer through phylogenetic analysis

    Timing evolution of lobular breast cancer through phylogenetic analysis oleh Danai Fimereli, David Venet, Mattia Rediti, Bram Boeckx, Marion Maetens, Samira Majjaj, Ghizlane Rouas, Caterina Marchio, Francois Bertucci, Odette Mariani, Maria Capra, Giuseppina Bonizzi, Federica Contaldo, Christine Galant, Gert Van den Eynden, Roberto Salgado, Elia Biganzoli, Anne Vincent-Salomon, Giancarlo Pruneri, Denis Larsimont, Diether Lambrechts, Christine Desmedt, David N. Brown, Françoise Rothé, Christos Sotiriou

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

    Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials oleh Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex

    Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex oleh Sung-Bae Kim, Taco W Kuijpers, Christos Sotiriou, Serena Di Cosimo, Jens Huober, Rebecca Roylance, Anton T J Tool, Dieke J van Rees, Bart Klein, Panagiota Bouti, Karin Schornagel, Robin van Bruggen, Hanke L Matlung, Paul J H Verkuijlen, Michel van Houdt, David Venet, Sarra El-Abed, Miguel Izquierdo, Sébastien Guillaume, Cristina Saura, Timo K van den Berg

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

    Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast ca... oleh Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells

    Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells oleh Clara Gómez-Aleza, Bastien Nguyen, Guillermo Yoldi, Marina Ciscar, Alexandra Barranco, Enrique Hernández-Jiménez, Marion Maetens, Roberto Salgado, Maria Zafeiroglou, Pasquale Pellegrini, David Venet, Soizic Garaud, Eva M. Trinidad, Sandra Benítez, Peter Vuylsteke, Laura Polastro, Hans Wildiers, Philippe Simon, Geoffrey Lindeman, Denis Larsimont, Gert Van den Eynden, Chloé Velghe, Françoise Rothé, Karen Willard-Gallo, Stefan Michiels, Purificación Muñoz, Thierry Walzer, Lourdes Planelles, Josef Penninger, Hatem A. Azim, Sherene Loi, Martine Piccart, Christos Sotiriou, Eva González-Suárez

    Diterbitkan 2020-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

    Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomize... oleh Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: